Bring drugs to market, faster
Abzu drives new discoveries and reduces R&D costs for biotech and pharma.
ACCELERATING DRUG DEVELOPMENT
Abzu closes the drug and target discovery loop
Understand the basis of disease, and identify novel points of intervention.
Determine the underlying mechanisms to optimize high-throughput screening.
Preclinical and clinical
Reveal drug-target interaction signatures from in vivo, in vitro, and in silico data.
Improve hit-rate by explaining selectivity, toxicity, and activity drivers.
Abzu recognized as a Cool Vendor in artificial intelligence
Abzu is named a “Cool Vendor” in the 2022 Gartner® “AI Governance and Responsible AI — From Principles to Practice” report.
What makes Abzu unique?
Abzu was born from the desire to challenge the fundamental assumptions of contemporary, black-box AI. Watch Abzu’s story in 3 minutes.
It’s easy to get in touch with an Abzoid.
Fill out the form below, and an Abzoid will be in touch in 24 hours.